Misinterpretation of the effect of amlodipine on cytosolic calcium concentration with fura-2 fluorospectrometry.
Due to its high sensitivity, reproducibility and reliability, fura-2 is one of the most preferred tools to quantify Ca2+ levels. Recently, using fura-2/AM, some calcium channel blockers (CCBs) have been reported to have inhibitory effects on intracellular Ca2+ signaling even in nonexcitable cells that do not possess voltage-dependent Ca2+ channels (VDCC). Some CCBs are known to be photosensitive. Since photosensitive chemicals often have autofluorescent property, it is likely that CCBs with autofluorescence interfere with the fluorescent dye probes for Ca2+, which may cause misinterpretation of the results. The aim of this study was to clarify the characteristics of various CCBs on Ca2+ fluorescent probes and to identify proper fluorescent probes for each CCB to allow reliable Ca2+ measurement using endothelial cells (ECs), which possess no VDCC. Thapsigargin (TG, Ca2+-ATPase inhibitor on endoplasmic reticulum) increased fura-2 F340/F380 ratio from 0.75+/-0.06 to 4.28+/-0.32, suggesting the increase in cytosolic Ca2+ concentrations in ECs. Verapamil, nifedipine and nicardipine did not affect TG-induced increase in fura-2 F340/F380 ratio; however, amlodipine dose dependently inhibited the rise of fura-2 ratio by 24% at 100 nM, by 55% at 1 microM and by 82% at 10 microM, respectively, in ECs. In ex vivo experiments without cells, due to the autofluorescence of amlodipine excited by ultraviolet (UV light), amlodipine itself boosted the intensity of F380 much more than it did that of F340, which results in a decrease in F340/F380 ratio of fura-2 fluorescence. Rhod-2/AM, a fluorescent probe of which the excitation wavelength is out of the excitation spectrum of amlodipine, showed that amlodipine did not affect TG-induced intracellular Ca2+ increase in ECs. When the effect of amlodipine on intracellular Ca2+ concentration is assessed, fura-2 fluorospectrometry should not be used due to fluorescent interaction between amlodipine and fura-2, and using rhod-2 is strongly recommended.
Asai
Masayoshi
M
Internal Medicine III, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takeuchi
Kazuhiko
K
Uchida
Shinya
S
Urushida
Tsuyoshi
T
Katoh
Hideki
H
Satoh
Hiroshi
H
Yamada
Shizuo
S
Hayashi
Hideharu
H
Watanabe
Hiroshi
H
D017311:Amlodipine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000166:cytology / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D016257:Fura-2 / Q000378:metabolism; D006575:Heterocyclic Compounds, 3-Ring / Q000378:metabolism; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013552:Swine
D002121:Calcium Channel Blockers; D005456:Fluorescent Dyes; D006575:Heterocyclic Compounds, 3-Ring; C068483:rhod-2; D017311:Amlodipine; D002118:Calcium; D016257:Fura-2